Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01023737 · ClinicalTrials.gov registry record · Phase 1
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
A Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT01023737 is a Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 72 participants.
The verdict
NCT01023737, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study is an open label non randomized study of hydroxychloroquine (HCQ) with histone deacetylase (HDAC) inhibitor Vorinostat in patients with advanced solid tumors to determine the maximum tolerated dose (MTD) and to evaluate the safety and antitumor activity of this drug combination.
Interventions
- DRUG Vorinostat
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2009-11 |
| Est. Completion | 2023-01-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01023737
The ClinicalTrials.gov registry entry for NCT01023737 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vorinostat is the first listed.
NCT01023737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01023737 about?
NCT01023737 is a clinical study titled "Hydroxychloroquine + Vorinostat in Advanced Solid Tumors". This study is an open label non randomized study of hydroxychloroquine (HCQ) with histone deacetylase (HDAC) inhibitor Vorinostat in patients with advanced solid tumors to determine the maximum tolerated dose (MTD) and to evaluate the safety and antitumor activity of this drug combination.
What is the current status of trial NCT01023737?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2009-11. Estimated completion is 2023-01-08.
What interventions are being tested in trial NCT01023737?
The interventions under investigation include: Vorinostat (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT01023737?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.